• Coloplast lowered its 2030 growth ambition in its 2025/26 annual report, reflecting US biologics reimbursement changes, pricing pressure and inflation.
• Strong Chronic Care demand supported performance, while China remained weak; Men's Health drove growth in Interventional Urology.
• US outpatient reimbursement changes disrupted Kerecis sales, prompting a sharper focus on inpatient care and a reduced outpatient organization.
• Biologics is expected to return to growth in 2026/27, supported by the inpatient focus.
• A resource reallocation program will fund increased investment in innovation and commercial expansion, with full benefits expected in 2027/28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coloplast A/S published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.